Meeting
2019 Genitourinary Cancers Symposium
A phase II study of ribociclib in men with unresectable, incurable teratoma with recent progression.
Authors
Daniel E. Castellano
Hospital Universitario 12 de Octubre, Madrid, Spain
Daniel E. Castellano , David I. Quinn , Darren R. Feldman , Karim Fizazi , Xavier Garcia del Muro , Jourik A. Gietema , Richard C. Lauer , Mary Elizabeth Ising , Mehreteab Aregay , Adam Samuel Crystal , David J. Vaughn
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Prostate Cancer; Urothelial Carcinoma; Penile, Urethral, Testicular, and Adrenal Cancers
Track
Urothelial Carcinoma,Prostate Cancer,Penile, Urethral, Testicular, and Adrenal Cancers
Sub Track
Testicular Cancer
Clinical Trial Registration Number
NCT02300987
Citation
J Clin Oncol 37, 2019 (suppl 7S; abstr 517)
DOI
10.1200/JCO.2019.37.7_suppl.517
Abstract #
517
Poster Bd #
M4
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
LEONARDA-1: Phase III randomized study of lerociclib plus fulvestrant in patients with HR+, HER2- locally advanced or metastatic breast cancer that has progressed on prior endocrine therapy.
First Author: Binghe Xu
Poster
2016 Genitourinary Cancers Symposium
Cyclin-dependent kinase 4/6 inhibition for the treatment of mature teratoma germ cell tumor: Long-term follow-up of a phase II study.
First Author: Vivek Narayan
Poster
2024 ASCO Annual Meeting
Neoadjuvant adebrelimab plus dalpiciclib in HPV-negative locally advanced head and neck squamous cell carcinoma: A phase II clinical trial.
First Author: Lei Liu
Poster
2023 ASCO Annual Meeting
Efficacy and safety of tenalisib, a PI3K δ/γ and SIK3 inhibitor, in patients with locally advanced or metastatic breast cancer: Updated results from an on-going phase II study.
First Author: Tamta Makharadze